Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.005 · Cited by 519

The variant gambit: COVID-19’s next move

Plante, J. A., Mitchell, B. M., Plante, K. S., Debbink, K., Weaver, S. C., & Menachery, V. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.020 · Cited by 328

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Edara, V. V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G., Nyhoff, L. E., Adelman, M. W., Fineman, R., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.009 · Cited by 224

Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing Antibodies

Vanderheiden, A., Edara, V. V., Floyd, K. A., Kauffman, R. C., Mantus, G. E., Anderson, E. J., Rouphael, N., Edupuganti, S., Shi, P., Menachery, V. D., et al. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.116 · Cited by 134

Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron VariantPreprint

Lyke, K. E., Atmar, R. L., Islas, C. P. D., Posavad, C. M., Szydlo, D. W., PaulChourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4061187 · Cited by 31

Vaccination is the most effective and best way to avoid the disease of COVID‐19

Lotfi, H., Mazar, M. G., Ei, N. M. H., Fahim, M., & Yazdi, N. S. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.946 · Cited by 33

Interspecies Jumping of Bat Coronaviruses

Wong, A. C. P., Lau, S. K. P., & Woo, P. C. Y. (2021) · Viruses · doi:10.3390/v13112188 · Cited by 30

Outcomes of SARS-CoV-2 Infection in Unvaccinated Compared With Vaccinated Solid Organ Transplant Recipients: A Propensity Matched Cohort Study

Hall, V. G., Al-Alahmadi, G., Solera, J. T., Marinelli, T. M., Cardinal, H., Prasad, G. V. R., Serres, S. A. D., Isaac, D., Mainra, R., Lamarche, C., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004178 · Cited by 31

Accurate identification of SARS-CoV-2 variant delta using graphene/CRISPR-dCas9 electrochemical biosensor

Yang, B., Zeng, X., Zhang, J. C., Kong, J., & Fang, X. (2022) · Talanta · doi:10.1016/j.talanta.2022.123687 · Cited by 31

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals

Lederer, K., Parvathaneni, K., Painter, M. M., Bettini, E., Agarwal, D., Lundgreen, K. A., Weirick, M., Goel, R. R., Xu, X., Drapeau, E. M., et al. (2021) · doi:10.1101/2021.09.16.21263686 · Cited by 179

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates

Routhu, N. K., Stampfer, S. D., Lai, L., Akhtar, A., Tong, X., Yuan, D., Chicz, T. M., McNamara, R. P., Jakkala, K., Davis-Gardner, M. E., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg7015 · Cited by 28

Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants

Cardemil, C. V., Cao, Y., Posavad, C. M., Badell, M. L., Bunge, K. E., Mulligan, M. J., Parameswaran, L., Olson‐Chen, C., Novak, R. M., Brady, R. C., et al. (2024) · PEDIATRICS · doi:10.1542/peds.2023-064252 · Cited by 29

Monitoring the SARS-CoV-2 pandemic: screening algorithm with single nucleotide polymorphism detection for the rapid identification of established and emerging variants

Mertens, J. C., Coppens, J., Loens, K., Mercier, M. L., Xavier, B. B., Lammens, C., Vandamme, S., Jansens, H., Goossens, H., & Matheeussen, V. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.007 · Cited by 28

Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations

Showers, W. M., Leach, S. M., Kechris, K. J., & Strong, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105153 · Cited by 35

mRNA COVID-19 vaccine elicits potent adaptive immune response without the persistent inflammation seen in SARS-CoV-2 infectionPreprint

Ivanova, E. N., Shwetar, J., Devlin, J. C., Buus, T. B., Gray-Gaillard, S. L., Koide, A., Cornelius, A. R., Samanovic, M. I., Herrera, A. M., Mimitou, E. P., et al. (2021) · medRxiv · doi:10.1101/2021.04.20.21255677 · Cited by 29

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants

Wang, R., Sun, C., Ma, J., Yu, C., Kong, D., Chen, M., Liu, X., Zhao, D., Gao, S., Kou, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10050702 · Cited by 26

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern

Yuan, M., Chen, X., Zhu, Y., Dong, X., Liu, Y., Qian, Z., Ye, L., & Liu, P. (2022) · Journal of Virology · doi:10.1128/jvi.00775-22 · Cited by 27

Enhancing epitope of PEDV spike protein

Thavorasak, T., Chulanetra, M., Glab-ampai, K., Mahasongkram, K., Saelim, N., Teeranitayatarn, K., Songserm, T., Yodsheewan, R., Nilubol, D., Chaicumpa, W., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.933249 · Cited by 26

What Happens to the Immune System after Vaccination or Recovery from COVID-19?

Tiyo, B. T., Schmitz, G. J. H., Ortega, M. M., da Silva, L. T., de Almeida, A., Oshiro, T. M., & Duarte, A. J. D. S. (2021) · Life · doi:10.3390/life11111152 · Cited by 28

Rapid test to assess the escape of SARS-CoV-2 variants of concern

Heggestad, J. T., Britton, R. J., Kinnamon, D., Wall, S. A., Joh, D. Y., Hucknall, A., Olson, L. B., Anderson, J. G., Mazur, A., Wolfe, C. R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abl7682 · Cited by 25

Crystal Structures of Bat and Human Coronavirus ORF8 Protein Ig-Like Domain Provide Insights Into the Diversity of Immune Responses

Chen, X., Zhou, Z., Huang, C., Zhou, Z., Kang, S., Huang, Z., Jiang, G., Hong, Z., Chen, Q., Yang, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.807134 · Cited by 27

Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines

Yaqinuddin, A., Shafqat, A., Kashir, J., & AlKattan, K. M. (2021) · Vaccines · doi:10.3390/vaccines9080914 · Cited by 25

SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays

Padoan, A., Cosma, C., Bonfante, F., Rocca, F. D., Barbaro, F., Santarossa, C., Dall’Olmo, L., Pagliari, M., Bortolami, A., Cattelan, A. M., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.028 · Cited by 22

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants

Junker, D., Dulovic, A., Becker, M., Wagner, T. R., Kaiser, P. D., Traenkle, B., Kienzle, K., Bunk, S., Struemper, C., Haeberle, H. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10987-2 · Cited by 25

Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies

Li, R., Mor, M., Ma, B., Clark, A. E., Alter, J., Werbner, M., Lee, J. C., Leibel, S. L., Carlin, A. F., Dessau, M., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03739-5 · Cited by 25

Comparative docking studies of drugs and phytocompounds for emerging variants of SARS-CoV-2

Chugh, A., Sehgal, I., Khurana, N., Verma, K., Rolta, R., Vats, P., Salaria, D., Fadare, O. A., Awofisayo, O., Verma, A., et al. (2023) · 3 Biotech · doi:10.1007/s13205-022-03450-6 · Cited by 25

Variants of SARS-CoV-2: Influences on the Vaccines’ Effectiveness and Possible Strategies to Overcome Their Consequences

Rabaan, A. A., Al-Ahmed, S. H., Albayat, H., Alwarthan, S. M., Alhajri, M. M., Najim, M. A., Alshehail, B. M., Al-Adsani, W., Alghadeer, A., Abduljabbar, W. A., et al. (2023) · Medicina · doi:10.3390/medicina59030507 · Cited by 26

Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review

Cheng, Z. J., Xue, M., Zheng, P., Lyu, J., Zhan, Z., Hu, H., Zhang, Y., Zhang, X. D., & Sun, B. (2021) · Vaccines · doi:10.3390/vaccines9080869 · Cited by 26

Developing an Amplification Refractory Mutation System-Quantitative Reverse Transcription-PCR Assay for Rapid and Sensitive Screening of SARS-CoV-2 Variants of Concern

Xiong, D., Zhang, X., Shi, M., Wang, N., He, P., Dong, Z., Zhong, J., Luo, J., Wang, Y., Yu, J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01438-21 · Cited by 24

Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail

Addetia, A., Park, Y., Starr, T. N., Greaney, A. J., Sprouse, K. R., Bowen, J. E., Tilles, S. W., Voorhis, W. C. V., Bloom, J. D., Corti, D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112621 · Cited by 24

mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection

Ivanova, E. N., Shwetar, J., Devlin, J. C., Buus, T. B., Gray-Gaillard, S. L., Koide, A., Cornelius, A. R., Samanovic, M. I., Herrera, A. M., Mimitou, E. P., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108572 · Cited by 28

Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2

Peng, L., Renauer, P. A., Ökten, A., Fang, Z., Park, J. J., Zhou, X., Lin, Q., Dong, M. B., Filler, R., Xiong, Q., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100634 · Cited by 21

An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination

Carreño, J. M., Raskin, A. J., Singh, G., Tcheou, J., Kawabata, H., Gleason, C., Srivastava, K., Vigdorovich, V. I., Dambrauskas, N., Gupta, S. L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo2847 · Cited by 24

Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development

He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 25

Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe—short- And long-term Immune reSponSe evAluatioN in health Care workErs

Pani, A., Cento, V., Vismara, C., Campisi, D., Ruscio, F. D., Romandini, A., Senatore, M., Schenardi, P. A., Gagliardi, O. M., Giroldi, S., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.08.013 · Cited by 22

Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India

Singh, P., Sharma, K. K., Singh, P., Bhargava, A., Negi, S. S., Sharma, P., Bhise, M. P., Tripathi, M. K., Jindal, A., & Nagarkar, N. M. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105404 · Cited by 22

A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines

Nanthapisal, S., Puthanakit, T., Jaru-Ampornpan, P., Nantanee, R., Sodsai, P., Himananto, O., Sophonphan, J., Suchartlikitwong, P., Hiransuthikul, N., Angkasekwinai, P., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.036 · Cited by 21

ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants

Seow, J., Graham, C., Hallett, S. R., Lechmere, T., Maguire, T. J. A., Huettner, I., Cox, D., Khan, H., Pickering, S., Roberts, R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110757 · Cited by 18

Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection

Kumar, P., Mathayan, M., Smieszek, S., Przychodzen, B., Koprivica, V., Birznieks, G., Polymeropoulos, M., & Prabhakar, B. S. (2022) · Virology · doi:10.1016/j.virol.2022.05.004 · Cited by 18

Clinical outcomes and phylogenetic analysis in reflection with three predominant clades of SARS‐CoV‐2 variants

Ali, K. M., Rashid, P., Ali, A. M., Tofiq, A. M., Salih, G., Dana, O., & Rostam, H. M. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14004 · Cited by 15

Spectrum of neuroimaging mimics in children with COVID-19 infection

Wong, A. M., & Toh, C. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.11.005 · Cited by 22

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concernPreprint

Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/z4x7t · Cited by 22

Application of omics technology to combat the COVID‐19 pandemic

Yang, J., Yan, Y., & Zhong, W. (2021) · MedComm · doi:10.1002/mco2.90 · Cited by 20

Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?

Tran, B. M., Deliyannis, G., Hachani, A., Earnest, L., Torresi, J., & Vincan, E. (2022) · Organoids · doi:10.3390/organoids1010002 · Cited by 21

A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike

van der Velden, Y. U., Grobben, M., Caniels, T. G., Burger, J. A., Poniman, M., Oomen, M., Rijnstra, E. S.-V., Tejjani, K., Guerra, D., Kempers, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07590-w · Cited by 21

Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination

Das, S. R., Singh, J., Shaman, H., Singh, B., Anantharaj, A., Patil, S., Pandey, R., Lodha, R., Pandey, A. K., & Medigeshi, G. R. (2022) · Nature Communications · doi:10.1038/s41467-022-31170-1 · Cited by 21

Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults

Gupta, S. L., Mantus, G. E., Manning, K. E., Ellis, M. L., Patel, M., Ciric, C. R., Lu, A., Turner, J. S., O’Halloran, J. A., Presti, R. M., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00582-22 · Cited by 23

β2-adrenergic signaling promotes higher-affinity B cells and antibodies

Ben-Shalom, N., Sandbank, E., Abramovitz, L., Hezroni, H., Levine, T., Trachtenberg, E., Fogel, N., Mor, M., Yefet, R., Stoler‐Barak, L., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.06.020 · Cited by 21

Variantes de SARS-CoV-2, una historia todavía inacabada

Pérez-Abeledo, M., & Moreno, J. C. S. (2021) · Vacunas · doi:10.1016/j.vacun.2021.06.003 · Cited by 20

A Review of Different Vaccines and Strategies to Combat COVID-19

Sabitha, S., Shobana, N., Prakash, P., Padmanaban, S., Sathiyasree, M., Saigeetha, S., Chakravarthi, S., Uthaman, S., Park, I., & Samrot, A. V. (2022) · Vaccines · doi:10.3390/vaccines10050737 · Cited by 29

Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies

Rouhani, S. J., Yu, J., Olson, D. J., Zha, Y., Pezeshk, A., Cabanov, A., Pyzer, A. R., Trujillo, J., Derman, B. A., O’Donnell, P. H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004766 · Cited by 21

When the Dust Has Settled: Calculation of Binding Affinities from First Principles for SARS-CoV-2 Variants with Quantitative Accuracy

de Lacam, E. G. C., Blazhynska, M., Chen, H., Gumbart, J. C., & Chipot, C. J. (2022) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.2c00604 · Cited by 19

Neurological pathophysiology of SARS‐CoV‐2 and pandemic potential RNA viruses: a comparative analysis

Chakravarty, N., Senthilnathan, T., Paiola, S. G., Gyani, P., Cario, S. C., Urena, E., Jeysankar, A., Jeysankar, P., Irudayam, J. I., Subramanian, S. N., et al. (2021) · FEBS Letters · doi:10.1002/1873-3468.14227 · Cited by 19

Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy

Baj, A., Novazzi, F., Ferrante, F. D., Genoni, A. P., Tettamanzi, E., Catanoso, G., Gasperina, D. D., Dentali, F., Focosi, D., & Maggi, F. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1994356 · Cited by 18

A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants

Rabaan, A. A., Mutair, A. S. A., Hajissa, K., Alfaraj, A. H., Al-Jishi, J. M., Alhajri, M. M., Alwarthan, S. M., Alsuliman, S. A., Al-Najjar, A. H., Al-Zaydani, I. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10101655 · Cited by 18

COVID‐19 cooling: Nanostrategies targeting cytokine storm for controlling severe and critical symptoms

Zheng, Y., Li, Y., Mao, L., Wang, R., Jiang, Y., Zhao, M., Lu, J. L., Li, R., Li, X., & Shi, S. (2023) · Medicinal Research Reviews · doi:10.1002/med.21997 · Cited by 18

Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity

Runnstrom, M. C., Lamothe, P. A., Faliti, C. E., Cheedarla, N., Moreno, A., Suthar, M. S., Nahata, R., Ravindran, M., Haddad, N. S., Morrison-Porter, A., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.03.029 · Cited by 18

Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight

Khan, M. I., Baig, M. H., Mondal, T., Alorabi, M., Sharma, T., Dong, J.-J., & Choi, Y. (2021) · Viruses · doi:10.3390/v13112295 · Cited by 18

Temporal lineage replacements and dominance of imported variants of concern during the COVID-19 pandemic in Kenya

Kimita, G., Nyataya, J., Omuseni, E., Sigei, F., Lemtudo, A. P., Muthanje, E. M., Andika, B., Liyai, R., Githii, R., Masakhwe, C., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00167-8 · Cited by 15

Evaluation of the clinical and analytical performance of the Seegene allplex™ SARS-CoV-2 variants I assay for the detection of variants of concern (VOC) and variants of interests (VOI)

Caza, M., Hogan, C. A., Jassem, A. N., Prystajecky, N., Hadzic, A., & Wilmer, A. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104996 · Cited by 17

Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine

Kuse, N., Zhang, Y., Chikata, T., Nguyen, H. T., Oka, S., Gatanaga, H., & Takiguchi, M. (2022) · Nature Communications · doi:10.1038/s41467-022-32989-4 · Cited by 17

A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned

O’Connor, M. A., Hawman, D. W., Meade-White, K. D., Leventhal, S. S., Song, W., Randall, S., Archer, J. F., Lewis, T. B., Brown, B., Fredericks, M., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011298 · Cited by 18

Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults

Joshi, D., Nyhoff, L. E., Zarnitsyna, V. I., Moreno, A., Manning, K. E., Linderman, S. L., Burrell, A. R., Stephens, K., Norwood, C., Mantus, G. E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107967 · Cited by 17

Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera

Hu, J., Wei, X., Jin, X., Peng, P., Xu, F.-L., Wu, K., Luo, F., Jin, A., Fang, L., Liu, B., et al. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.11.007 · Cited by 25

SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19

Liang, H., Wu, Y., Yau, V., Yin, H.-X., Lowe, S., Bentley, R., Ahmed, M. A., Zhao, W., & Sun, C. (2022) · Vaccines · doi:10.3390/vaccines10091538 · Cited by 16

Putting ethics and clinical decision making before politics: requiring COVID-19 immunization for Solid Organ Transplantation (SOT) Candidates and their Support Team

Kuczewski, M. G., Wasson, K., Hutchison, P. J., & Dilling, D. F. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.10.001 · Cited by 16

Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants

Al-Khatib, H. A., Smatti, M. K., Ali, F. H., Zedan, H. T., Thomas, S., Ahmed, M. N., Kahlout, R. A. E., Bader, M. A. A., Elgakhlab, D., Coyle, P. V., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105438 · Cited by 14

A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo

Aschner, C. B., Muthuraman, K., Kucharska, I., Cui, H., Prieto, K., Nair, M. S., Wang, M., Huang, Y., Christie-Holmes, N., Poon, B., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf4549 · Cited by 15

Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19

D’Rozario, R., Raychaudhuri, D., Bandopadhyay, P., Sarif, J., Mehta, P., Liu, C. S. C., Sinha, B. P., Roy, J., Bhaduri, R., Das, M., et al. (2023) · Viruses · doi:10.3390/v15020549 · Cited by 15

Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants

Changrob, S., Halfmann, P., Liu, H., Torres, J. L., McGrath, J. J. C., Ozorowski, G., Li, L., Wilbanks, G. D., Kuroda, M., Maemura, T., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166844 · Cited by 13

What makes SARS‐CoV‐2 unique? Focusing on the spike protein

Qian, J., Zhang, S.-C., Wang, F., Li, J., & Zhang, J. (2024) · Cell Biology International · doi:10.1002/cbin.12130 · Cited by 16

Mutational Landscape and Interaction of SARS-CoV-2 with Host Cellular Components

Srivastava, M., Hall, D., Omoru, O. B., Gill, H. M., Smith, S., & Janga, S. C. (2021) · Microorganisms · doi:10.3390/microorganisms9091794 · Cited by 13

Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients

Takeshita, M., Nishina, N., Moriyama, S., Takahashi, Y., Ishii, M., Saya, H., Kondo, Y., Kaneko, Y., Suzuki, K., Fukunaga, K., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108999 · Cited by 12

Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants

Hu, Y., Hu, J., Gong, H., Danchin, A., Sun, R., Chu, H., Hung, I. F., Yuen, K., To, K. K., Zhang, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861050 · Cited by 15

The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice

Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 16

Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines

Alesci, A., Gitto, M., Kotańska, M., Cascio, P. L., Miller, A., Nicosia, N., Fumia, A., & Pergolizzi, S. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.08.004 · Cited by 14

Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies

Chang, A., Koff, J. L., Lai, L., Orellana-Noia, V. M., Surati, M. J., Leal, A. M. K., Ellis, M. L., Wali, B., Moreno, A., Linderman, S. L., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009475 · Cited by 13

Syndecan-4 Is a Key Facilitator of the SARS-CoV-2 Delta Variant’s Superior Transmission

Hudák, A., Veres, G., Letoha, A., Szilák, L., & Letoha, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020796 · Cited by 13

Association of gut microbial dysbiosis with disease severity, response to therapy and disease outcomes in Indian patients with COVID-19

Talukdar, D., Bandopadhyay, P., Ray, Y., Paul, S. R., Sarif, J., D’Rozario, R., Lahiri, A., Das, S., Bhowmik, D., Chatterjee, S., et al. (2023) · Gut Pathogens · doi:10.1186/s13099-023-00546-z · Cited by 14

Mathematical modeling for Delta and Omicron variant of SARS-CoV-2 transmission dynamics in Greece

Liossi, S., Tsiambas, E., Maipas, S., Papageorgiou, E., Lazaris, A. C., & Kavantzas, N. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.07.002 · Cited by 13

Contribution of High Viral Loads, Detection of Viral Antigen and Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity

Buder, F., Bauswein, M., Magnus, C. L., Audebert, F., Lang, H., Kundel, C., Distler, K., Reuschel, E., Lubnow, M., Müller, T. M., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab415 · Cited by 12

Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Chong, Z. X., Liew, W.-P.-P., Ong, H. K., Yong, C. Y., Shit, C. S., Ho, W. Y., Ng, S., & Yeap, S. K. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153565 · Cited by 13

SARS-CoV-2 variants, a still unfinished story

Pérez-Abeledo, M., & Moreno, J. C. S. (2021) · Vacunas (English Edition) · doi:10.1016/j.vacune.2021.10.003 · Cited by 12

SARS-CoV-2 Virology

Li, Y., & Li, J. Z. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.004 · Cited by 14

Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies

Chang, S., Liu, H., Wu, J., Xiao, W., Chen, S., Qiu, S., Duan, G., Song, H., & Zhang, R. (2022) · Vaccines · doi:10.3390/vaccines10030469 · Cited by 12

SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise

Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12

XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variantsPreprint

Jain, S., Kumar, S., Lai, L., Linderman, S. L., Malik, A. A., Ellis, M. L., Godbole, S., Solis, D., Sahoo, M. K., Bechnak, K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.03.578771 · Cited by 12

Coronavirus Genus Recognition Based on Prototype Virus Variants

Chaley, M. B., & Андреевич, К. В. (2022) · Mathematical Biology and Bioinformatics · doi:10.17537/2022.17.10 · Cited by 11

A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization

Mattoo, S.-U.-S., & Myoung, J. (2021) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2111.11026 · Cited by 11

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination

Chatsiricharoenkul, S., Niyomnaitham, S., Posen, H. J., Toh, Z. Q., Licciardi, P. V., Wongprompitak, P., Duangchinda, T., Pakchotanon, P., Chantima, W., & Chokephaibulkit, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1010835 · Cited by 12

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases

Raptis, C., Berger, C. T., Ciurea, A., Andrey, D. O., Polysopoulos, C., Lescuyer, P., Maletic, T., Riek, M., Scherer, A., von Loga, I., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016927 · Cited by 12

A SARS-CoV-2: Companion Animal Transmission and Variants Classification

Pandit, R., & Matthews, Q. L. (2023) · Pathogens · doi:10.3390/pathogens12060775 · Cited by 11

The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins

Kumar, S., Jain, S., Wali, B., Zarnitsyna, V. I., Joshi, D., Ellis, M. L., Lai, L., Malik, A. A., McPherson, T., Godbole, S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu8067 · Cited by 12

Vaccine efficacy in mutant SARS-CoV-2 variants.

Kandikattu, H. K., Yadavalli, C. S., Venkateshaiah, S. U., & Mishra, A. (2021) · PubMed · doi:10.264195/ijcbp.isp · Cited by 10

SARS-CoV-2 and Its Variants: The Pandemic of Unvaccinated

Angius, F., Pala, G., & Manzin, A. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.749634 · Cited by 10

Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants

Oliynyk, O. V., Barg, W., Oliynyk, Y. V., Дубров, С. О., Gurianov, V. G., & Rorat, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071103 · Cited by 10

Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings

Panahi, Y., Einollahi, B., Beiraghdar, F., Darvishi, M., Fathi, S., Javanbakht, M., Shafiee, S., & Akhavan‐Sigari, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947602 · Cited by 10

Neutralization of recombinant RBD-subunit vaccine ZF2001-elicited antisera to SARS-CoV-2 variants including DeltaPreprint

Zhao, X., Zheng, A., Li, D., Zhang, R., Sun, H., Wang, Q., Gao, G. F., Han, P., & Dai, L. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.15.452504 · Cited by 10

Short-Term Immune Response After Inactivated SARS-CoV-2 (CoronaVac®, Sinovac) And ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) Vaccinations in Thai Health Care WorkersPreprint

Jantarabenjakul, W., Chantasrisawad, N., Puthanakit, T., Wacharapluesadee, S., Hirankarn, N., Ruenjaiman, V., Paitoonpong, L., Suwanpimolkul, G., Torvorapanit, P., Pradit, R., et al. (2021) · medRxiv · doi:10.1101/2021.08.27.21262721 · Cited by 10

Incidence and outcome of SARS-CoV-2 reinfection in the pre-Omicron era: A global systematic review and meta-analysis

Ismail, N. F., Rahman, A. E., Kulkarni, D., Zhu, F., Wang, X., Morales, G. D. C., Srivastava, A. K., Allen, K. E., Spinardi, J., Kyaw, M. H., et al. (2023) · Journal of Global Health · doi:10.7189/jogh.13.06051 · Cited by 10

Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination

Walmsley, S. L., Nabipoor, M., Qi, F., Lovblom, L. E., Ravindran, R., Colwill, K., Dayam, R. M., Tursun, T. R., Silva, A., Gingras, A., et al. (2024) · Vaccines · doi:10.3390/vaccines12060564 · Cited by 10

An Appraisal of the Current Scenario in Vaccine Research for COVID-19

Chong, W. C., Chellappan, D. K., Shukla, S. D., Peterson, G. M., Patel, R. P., Jha, N. K., Eri, R. D., Dua, K., Tambuwala, M. M., & Shastri, M. D. (2021) · Viruses · doi:10.3390/v13071397 · Cited by 9

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants

Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M. W., Cooper, D., Muik, A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00462-4 · Cited by 9

Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection

Doke, P. P., Gothankar, J. S., Doke, P. P., Kulkarni, M. M., Khalate, K. K., Shrivastava, S., Patil, J. R., & Arankalle, V. A. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2022.104979 · Cited by 9

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697

Neutralization of B.1.617.2 variant through antibodies elicited by ChAdOx1‐S, BBIBP‐CorV, and Gam‐COVID‐Vac in an Argentinean cohort

Blanco, S., Aguilar, J. J., Spinsanti, L., Díaz, A., Beranek, M., Rivarola, M. E., Fernández, E. A., Mangeaud, A. P., Konigheim, B. S., & Gallego, S. V. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28286

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variantPreprint

Edara, V. V., Lai, L., Sahoo, M. K., Floyd, K. A., Sibai, M., Solis, D., Flowers, M. W., Hussaini, L., Ciric, C. R., Bechnak, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.09.443299 · Cited by 100

Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination

Bonura, F., Genovese, D., Amodio, E., Calamusa, G., Sanfilippo, G. L., Cacioppo, F., Giammanco, A., Grazia, S. D., & Ferraro, D. (2022) · Vaccines · doi:10.3390/vaccines10060874 · Cited by 8

In vitro neutralizing activity of BNT162b2 mRNA‐induced antibodies against full B.1.351 SARS‐CoV‐2 variant

Serrano‐Conde, E., Leyva, A., Fuentes, A. P., de Salazar, A., Chueca, N., Pérez‐Castro, S., Regueiro, B. J., Rojas, A., Mendoza, J., Rojas, J., et al. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14417 · Cited by 3